A share price of Royalty Pharma plc [RPRX] is currently trading at $26.20, up 0.61%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RPRX shares have gain 2.70% over the last week, with a monthly amount glided 1.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Royalty Pharma plc [NASDAQ: RPRX] stock has seen the most recent analyst activity on June 03, 2024, when UBS downgraded its rating to a Neutral but kept the price target unchanged to $28 for it. On May 13, 2022, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $53 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $56 on April 27, 2022. JP Morgan upgraded its rating to a Overweight but $50 remained the price target by the analyst firm on April 14, 2022. In a note dated October 29, 2021, Citigroup upgraded an Buy rating on this stock but restated the target price of $50.
Royalty Pharma plc experienced fluctuations in its stock price throughout the past year between $24.05 and $31.66. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Royalty Pharma plc [NASDAQ: RPRX] shares were valued at $26.20 at the most recent close of the market. An investor can expect a potential return of 94.66% based on the average RPRX price forecast.
Analyzing the RPRX fundamentals
Trailing Twelve Months sales for Royalty Pharma plc [NASDAQ:RPRX] were 2.27B which represents 5.29% growth. Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at 0.68%, Pretax Profit Margin comes in at 0.76%, and Net Profit Margin reading is 0.51%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.17 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.85 points at the first support level, and at 25.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.46, and for the 2nd resistance point, it is at 26.72.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Royalty Pharma plc [NASDAQ:RPRX] is 1.54. In addition, the Quick Ratio stands at 1.54 and the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 6.81, the price to book ratio is 1.70 and price to earnings (TTM) ratio is 10.25.
